Membrane Target Detection for Leukemia Treatment

NCT04841447 | Recruiting

• 1 other identifier: 2018932
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.

Conditions

Hematological Malignancy

Outcome Measures

Primary Outcomes (1)

• DPP4 inhibitors measured in blood samples will be correlated with patient survival data.

  DPP4 inhibitors measured in blood samples will be used in vitro and in vivo a pre-clinical model.

  5 years

Interventions

Study sample collection OTHER

Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All hematological malignancy patients.

You may qualify if:

• All hematological malignancy patients.
• Must be 18 years old.

You may not qualify if:

• Participants with impaired decision-making capacities;
• Pregnant women or fetuses;
• Children (under 18 in Missouri, also dependent on State law);
• Non-viable neonates or neonates of uncertain viability (neonates=newborns);
• Non-English-speaking subjects;
• Prisoners.

Sponsors & Collaborators

• University of Missouri-Columbia: lead

Study Sites (1)

University of Missouri

Columbia, Missouri, 65212, United States

RECRUITING

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Xunlei Kang, MD.PhD

CONTACT

5738844524; kangxu@health.missouri.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 7, 2021
• First Posted: April 12, 2021
• Study Start: March 20, 2020
• Primary Completion (Estimated): March 20, 2027
• Study Completion (Estimated): March 20, 2027
• Last Updated: December 10, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)